BOSTON--(BUSINESS WIRE)-- #eye--Allotex Inc., a commercial-stage ophthalmic company with active European market adoption, today announced that the U.S. Food and Drug Administration (FDA) has conditionally approved its Investigational Device Exemption (IDE), authorizing the initiation of a U.S. clinical study for ALLO-1™, its proprietary tissue-based solution for presbyopia. This conditional IDE approval represents a significant step-change in value, transitioning Allotex from commercialization in Euro

BOSTON--(BUSINESS WIRE)-- #eye--Allotex Inc., a commercial-stage ophthalmic company with active European market adoption, today announced that the U.S. Food and Drug Administration (FDA) has conditionally approved its Investigational Device Exemption (IDE), authorizing the initiation of a U.S. clinical study for ALLO-1™, its proprietary tissue-based solution for presbyopia. This conditional IDE approval represents a significant step-change in value, transitioning Allotex from commercialization in Euro